$ALZN
Alzamend Neuro, Inc.

2022 Q4 Form 10-Q Financial Statement

#000121465922014779 Filed on December 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q2 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.573M $2.212M $1.834M
YoY Change -14.2% 138.5% 0.08%
% of Gross Profit
Research & Development $1.533M $1.661M $1.750M
YoY Change -12.4% 467.54% 123.29%
% of Gross Profit
Depreciation & Amortization $5.320K $3.550K
YoY Change
% of Gross Profit
Operating Expenses $1.533M $3.873M $3.584M
YoY Change -57.23% 217.45% 36.99%
Operating Profit -$3.106M -$3.584M
YoY Change -13.32%
Interest Expense $3.588K -$600.00 -$16.00K
YoY Change -122.43% -98.37% -70.69%
% of Operating Profit
Other Income/Expense, Net -$3.588K -$16.00K
YoY Change -77.57%
Pretax Income -$3.110M -$3.869M -$3.600M
YoY Change -13.61% 207.87% 34.79%
Income Tax
% Of Pretax Income
Net Earnings -$3.110M -$3.869M -$3.600M
YoY Change -13.61% 207.87% 34.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03 -$0.04
Diluted Earnings Per Share -$31.90K -$44.01K -$38.52K
COMMON SHARES
Basic Shares Outstanding 96.43M shares
Diluted Shares Outstanding 97.49M shares 93.46M shares

Balance Sheet

Concept 2022 Q4 2022 Q2 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.183M $14.06M $13.57M
YoY Change -32.34% 628.97% 231515.87%
Cash & Equivalents $9.183M $14.06M $13.57M
Short-Term Investments
Other Short-Term Assets $1.152M $349.7K $912.0K
YoY Change 26.27% -63.84% -4.99%
Inventory
Prepaid Expenses $742.0K
Receivables
Other Receivables
Total Short-Term Assets $10.33M $14.41M $14.50M
YoY Change -28.73% 394.87% 1376.78%
LONG-TERM ASSETS
Property, Plant & Equipment $90.49K $102.9K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $90.49K $102.9K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $10.33M $14.41M $14.50M
Total Long-Term Assets $90.49K $102.9K $0.00
Total Assets $10.42M $14.52M $14.50M
YoY Change -28.11% 398.4% 1376.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $648.1K $1.163M $1.128M
YoY Change -42.56% 130.91% -10.85%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $344.9K
YoY Change -100.0% -100.0% 7.91%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.637M $1.165M $1.475M
YoY Change 10.98% 29.49% -10.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.637M $1.165M $1.475M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.637M $1.165M $1.475M
YoY Change 10.98% 29.49% -10.51%
SHAREHOLDERS EQUITY
Retained Earnings -$35.34M -$29.19M
YoY Change 73.44%
Common Stock $9.549K $9.548K
YoY Change 41.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.787M $13.35M $13.03M
YoY Change
Total Liabilities & Shareholders Equity $10.42M $14.52M $14.50M
YoY Change -28.11% 398.4% 1376.78%

Cashflow Statement

Concept 2022 Q4 2022 Q2 2021 Q4
OPERATING ACTIVITIES
Net Income -$3.110M -$3.869M -$3.600M
YoY Change -13.61% 207.87% 34.79%
Depreciation, Depletion And Amortization $5.320K $3.550K
YoY Change
Cash From Operating Activities -$2.344M -$1.562M -$2.046M
YoY Change 14.57% 24.21% 215.76%
INVESTING ACTIVITIES
Capital Expenditures -$106.5K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$106.5K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.942M 700.0
YoY Change -100.0% 25.3% -99.85%
NET CHANGE
Cash From Operating Activities -2.344M -1.562M -2.046M
Cash From Investing Activities -106.5K 0.000
Cash From Financing Activities 0.000 3.942M 700.0
Net Change In Cash -2.344M 2.274M -2.045M
YoY Change 14.61% 20.39% 2322.97%
FREE CASH FLOW
Cash From Operating Activities -$2.344M -$1.562M -$2.046M
Capital Expenditures -$106.5K
Free Cash Flow -$1.456M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001677077
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
alxneuro Fair Value Of Warrants Issued In Connection With March2021 Securities Purchase Agreement Related Party
FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
alxneuro Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs
ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
alxneuro Fair Value Of Warrants Issued In Connection With Ipo
FairValueOfWarrantsIssuedInConnectionWithIpo
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35341560 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3109991 usd
us-gaap Net Income Loss
NetIncomeLoss
-6147065 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
alxneuro Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
P5Y7M13D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y0M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P2Y4M24D
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2022-10-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40483
dei Entity Registrant Name
EntityRegistrantName
ALZAMEND NEURO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1822909
dei Entity Address Address Line1
EntityAddressAddressLine1
3500 Lenox Rd NE
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30326
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
722-6303
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
ALZN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
96427624 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9182812 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14063811 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
409574 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
349723 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
742001 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
10334387 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
14413534 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
90489 usd
us-gaap Interest Expense
InterestExpense
29623 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3588 usd
CY2022Q2 us-gaap Assets
Assets
14516443 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102909 usd
CY2022Q4 us-gaap Assets
Assets
10424876 usd
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15995 usd
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95481790 shares
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5120 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-29623 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
648119 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1162850 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
989334 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2082 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1637453 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1164932 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1637453 usd
CY2022Q2 us-gaap Liabilities
Liabilities
1164932 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95494290 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95494290 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95481790 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9549 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
9548 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
59002729 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57419753 usd
CY2022Q4 alxneuro Note Receivable For Common Stock Related Party
NoteReceivableForCommonStockRelatedParty
-14883295 usd
CY2022Q2 alxneuro Note Receivable For Common Stock Related Party
NoteReceivableForCommonStockRelatedParty
-14883295 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35341560 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29194495 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8787423 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13351511 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10424876 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14516443 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1532985 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1750050 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2908940 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2666458 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1573418 usd
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1833884 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3233005 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3223715 usd
CY2022Q4 us-gaap Costs And Expenses
CostsAndExpenses
3106403 usd
CY2021Q4 us-gaap Costs And Expenses
CostsAndExpenses
3583934 usd
us-gaap Costs And Expenses
CostsAndExpenses
6141945 usd
us-gaap Costs And Expenses
CostsAndExpenses
5890173 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3106403 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3109991 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3583934 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3109991 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8787423 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6141945 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
15344256 usd
CY2021Q4 alxneuro Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
1280384 usd
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
700 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5890173 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
3588 usd
CY2021Q4 us-gaap Interest Expense
InterestExpense
15995 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-3599929 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13025411 usd
us-gaap Interest Expense
InterestExpense
5120 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13351511 usd
alxneuro Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
1582977 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-3599929 usd
us-gaap Net Income Loss
NetIncomeLoss
-6147065 usd
us-gaap Net Income Loss
NetIncomeLoss
-5919796 usd
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97488448 shares
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93458556 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97485119 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88148524 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
11181775 usd
CY2022Q4 alxneuro Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
715639 usd
us-gaap Net Income Loss
NetIncomeLoss
-6147065 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8787423 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2012945 usd
alxneuro Stockbased Compensation To Employees And Consultants
StockbasedCompensationToEmployeesAndConsultants
2020006 usd
alxneuro Stock Issued During Period Value New Issues2
StockIssuedDuringPeriodValueNewIssues2
2000000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
800 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1500000 usd
alxneuro Stock Issued During Period Value New Issues3
StockIssuedDuringPeriodValueNewIssues3
12911456 usd
us-gaap Net Income Loss
NetIncomeLoss
-5919796 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13025411 usd
us-gaap Net Income Loss
NetIncomeLoss
-6147065 usd
us-gaap Net Income Loss
NetIncomeLoss
-5919796 usd
us-gaap Depreciation
Depreciation
12420 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
29623 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1582977 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2020006 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
59851 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-55116 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
245251 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-514731 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
546217 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4880999 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3268834 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
800 usd
alxneuro Proceeds From Initial Public Offering Net Of Underwriters Discounts And Commissions And Issuance Costs
ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts
12911456 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14912256 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4880999 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
11643422 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14063811 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1929270 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9182812 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13572692 usd
alxneuro Fair Value Of Warrants Issued In Connection With March2021 Securities Purchase Agreement Related Party
FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty
4,799,742
alxneuro Fair Value Of Warrants Issued In Connection With Ipo
FairValueOfWarrantsIssuedInConnectionWithIpo
461,877
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Cash
Cash
9200000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27308117 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22562834 shares
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_z3X1smRq9SX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86C_zKGsVVCuKRkf">Accounting Estimates</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p>
CY2022Q2 alxneuro Long Term Debt Average Amount Of Outstanding
LongTermDebtAverageAmountOfOutstanding
14883295 usd
CY2022Q4 alxneuro Long Term Debt Average Amount Of Outstanding
LongTermDebtAverageAmountOfOutstanding
14883295 usd
CY2022Q4 alxneuro Prepaid Consulting Fees
PrepaidConsultingFees
46667 usd
CY2022Q2 alxneuro Prepaid Consulting Fees
PrepaidConsultingFees
186667 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
353330 usd
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
155880 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
9577 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7176 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
409574 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
349723 usd
CY2022Q2 alxneuro Prepaid Insurance1
PrepaidInsurance1
492000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10149788 shares
CY2022Q4 alxneuro Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
2.90
CY2022Q4 alxneuro Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
10149788 shares
CY2022Q4 alxneuro Unamortized Prepaid Expense
UnamortizedPrepaidExpense
353000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8800000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15700000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.16
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2219700 usd
alxneuro Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Cancelled Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited
1391671 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1391671 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.59
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
10191671 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14308329 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.16
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1777200 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13308329 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.18
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1777200 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11582230 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.08
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1777200 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
715639 usd
CY2021Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1280384 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1582977 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2020006 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 alxneuro Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
2.90
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
742000 usd
CY2022Q4 us-gaap Due To Other Related Parties Current And Noncurrent
DueToOtherRelatedPartiesCurrentAndNoncurrent
989000 usd

Files In Submission

Name View Source Status
0001214659-22-014779-index-headers.html Edgar Link pending
0001214659-22-014779-index.html Edgar Link pending
0001214659-22-014779.txt Edgar Link pending
0001214659-22-014779-xbrl.zip Edgar Link pending
alxneuro-20221031.xsd Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
r12522010q.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
alxneuro-20221031_def.xml Edgar Link unprocessable
alxneuro-20221031_pre.xml Edgar Link unprocessable
alxneuro-20221031_cal.xml Edgar Link unprocessable
alxneuro-20221031_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
r12522010q_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending